Results 181 to 190 of about 121,428 (266)

Whose Sustainability Counts? Board Governance, ESG Ratings, and Sustainable Development Goals: Evidence on the ESG–SDG Wedge

open access: yesBusiness Strategy and the Environment, EarlyView.
ABSTRACT Institutional investors increasingly rely on ESG ratings to evaluate financially material sustainability risks, while governments promote corporate alignment with the United Nations Sustainable Development Goals (SDGs). Because these frameworks differ substantially in capital market salience and monitoring intensity, board oversight may not ...
Mohamed Hegazy   +2 more
wiley   +1 more source

Machine learning‐assisted clone selection for intensified cell culture processes

open access: yesBiotechnology Progress, EarlyView.
Abstract Intensified fed‐batch processes are becoming increasingly prevalent among biomanufacturers due to their superior space–time yields relative to traditional, non‐intensified fed‐batch processes. However, the shift towards intensified manufacturing has unexpectedly made optimal clone selection more challenging.
Nicolas Wolnick   +6 more
wiley   +1 more source

Photogrammetric Reconstruction of 3D Human Anatomical Structures and Augmented Reality via Smartphone Technology

open access: yesClinical Anatomy, EarlyView.
ABSTRACT Limited access to cadavers necessitates the availability of digital resources for anatomy education. Smartphone‐based photogrammetry offers a promising solution for creating three‐dimensional (3D) and augmented reality (AR) models. This study compared two mobile photogrammetry applications (Qlone and Polycam) that have been used in modern ...
Sarita Phukwantong   +3 more
wiley   +1 more source

Association of an Early Resistance Genomic State With Early Progression Following CDK4/6 Inhibitor Therapy in HR+/HER2− Metastatic Breast Cancer

open access: yesCancer Nexus, EarlyView.
ABSTRACT CDK4/6 inhibitors combined with endocrine therapy are the standard first‐line treatment for hormone receptor‐positive (HR+) HER2‐negative metastatic breast cancer. However, a substantial proportion of patients experience early disease progression in routine practice. Clinicians currently lack practical tools at treatment initiation to identify
Mobina Shrestha   +3 more
wiley   +1 more source

CYP2C19 Genotype is Associated with Citalopram Treatment Outcomes in a Real‐World Setting

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 metabolizes various selective serotonin reuptake inhibitors (SSRIs) and genetic CYP2C19 variants are associated with SSRI tolerability and response. Yet, whether CYP2C19 variability also impacts citalopram response remained unclear. We here evaluated associations between CYP2C19 genotypes and citalopram prescription data of 11,079 patients from
Yoomi Park   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy